Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆

info:eu-repo/semantics/publishedVersio

ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia

The introduction of immunotherapy with monoclonal antibodies (mAbs) is a major step forward for adults and children with B-lineage acute lymphoblastic leukaemia (ALL) and will change the treatment paradigm substantially. With intensive multi-agent chemotherapy (ChT) in children with ALL, long-term cure has been achieved in ≥90% of patients; however, this approach is often associated with long-term sequelae. Until recently, aggressive ChT has also been used in adult patients, with an overall cure rate of 50%. Survival rates are higher (∼70%) in adolescents and young adults (AYAs) but lower (70 years. With haematopoietic stem cell transplantation (HSCT), cure can be achieved in approximately half of adults; however, this approach is also associated with substantial toxicity and treatment-related mortality (TRM) rates of 10%-20%